与 alpelisib 相关的眶周水肿。
Periorbital edema associated with alpelisib.
机构信息
Louisiana State University Health Sciences Center School of Medicine, 2020 Gravier St., New Orleans, LA 70112, USA.
Department of Dermatology, Faculty Center Tower, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Floor 11, Box 1452, Houston, TX 77030, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, 6655 Travis Street, Suite 700, Houston, TX 77030, USA.
出版信息
Cancer Treat Res Commun. 2022;32:100596. doi: 10.1016/j.ctarc.2022.100596. Epub 2022 Jun 22.
Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.
阿培利司是一种 α 同工型特异性磷脂酰肌醇 3-激酶（PI3K）抑制剂，获批与氟维司群联合用于治疗激素受体（HR）阳性、人表皮生长因子受体 2（HER2）阴性的转移性乳腺癌。阿培利司最常报告的不良反应包括高血糖、皮疹和胃肠道不适。虽然皮疹是阿培利司的已知靶标效应，但患者通常表现为麻疹样皮疹。我们描述了两例与阿培利司相关的眶周水肿病例。我们讨论了这种独特反应的临床发现、处理和预后。这些病例强调了皮肤科早期参与管理与阿培利司相关的不良皮肤事件的重要性。
Zotero 插件